ERBB2 and cervical cancer: The study also discusses uterine cervix cancer screening and patient socioeconomic factors that are likely to impact operationalization of triage HER2 immunohistochemistry prior to radiopharmaceutical selection intending to treat persistent, recurrent, or metastatic uterine cervix cancer.